emovis by FutureMeds’ Post

🚀 Great Insights into the Medtech world! 🌐 Just read an article by Dorothea Hecht in Schwäbische Zeitung: "Five reasons, why so many firms are acquired in Medtech" - https://lnkd.in/eG_iy8z5 As a Director at EY-Parthenon Strategy, I am concerned with M&A Strategy discussions in #Medtech day-in-and-out. Whether it's CDMO or OEM, we explore the allure of investing in Medtech companies regularly. #MedtechOEMs need capital to offer cutting-edge products, simplify patient safety, expand market reach via a strong sales force, and build strong internal capabilities to manage a cost efficient supply chain. On the other hand, #MedtechCDMOs must ramp up production capabilities, requiring not just capital but investments in top-notch engineers. Precision matters, and relying solely on purchased machinery won't cut it. Capital influx, especially through #PrivateEquity, will continue to be a crucial lever, not just for boosting the German Medtech sector but powering the entire German economy. Reach out if you're into investing in Medtech firms or want to elevate them in your portfolio. Let's shape the future together! 💡🌐 #MedtechInvesting #MandAStrategy

### Embracing Efficiency and Innovation: Roche's Path Forward Since joining Roche in 2019, I've observed firsthand the culture of resource wastage, departmental silos, and inefficiency that pervaded our operations. This was partly due to our past successes and high profit margins, which, while impressive, led to complacency in business operations and a lack of retrospective tracking. A recent article from Tages-Anzeiger on March 13, 2024, titled "Roche-Chef Thomas Schinecker: Shocked on His First Company Jet Ride," sheds light on the proactive steps taken by our new CEO, Thomas Schinecker, to address these issues. Schinecker's approach has been to cut excessive spending—starting with the cancellation of the company's private jets—unless absolutely necessary, underscoring a commitment to frugality. More importantly, Schinecker is driving a shift in R&D governance and collaboration, utilizing artificial intelligence to accelerate drug development and increase success rates. This move is critical as Roche has been facing inefficiencies in R&D output relative to our significant investments. Under his leadership, specific research goals have been set to change this narrative. I strongly agree with Schinecker's strategies, which align with my own views on the necessity for pharmaceutical companies to balance patient needs with profit and operational efficiency. As our old product patents expire and some new pipelines fail, the push towards pragmatism and enhanced efficiency is timely. Looking ahead, I am optimistic about Roche's transformation under Schinecker's leadership. His management style not only promises a more thrifty and grounded corporate culture but also enhances our connection with society. The steps we are taking are not just about improving internal processes but about setting a benchmark for governance and collaboration in the industry. This is how a century-old company like Roche can reinvent itself, ensuring we continue to lead in delivering innovative healthcare solutions while maintaining robust operational efficiency. Source Link in German:

🏥🇩🇪 𝙈𝙚𝙙𝙞𝙘𝙖𝙡 𝙩𝙚𝙘𝙝𝙣𝙤𝙡𝙤𝙜𝙮 𝙞𝙣 𝙂𝙚𝙧𝙢𝙖𝙣𝙮: 𝙀𝙭𝙘𝙚𝙡𝙡𝙚𝙣𝙩, 𝙗𝙪𝙩 𝙩𝙝𝙧𝙚𝙖𝙩𝙚𝙣𝙚𝙙! 🚀 The autumn survey of the German Medical Technology Association (BVMed) shows alarming results. Although Germany's medical technology sales has a 4.8 percent increase in turnover compared to 2022, the challenges are enormous. Here are the main reasons: 👇🏻 1. 𝘽𝙪𝙧𝙚𝙖𝙪𝙘𝙧𝙖𝙘𝙮 𝙖𝙣𝙙 𝙧𝙚𝙜𝙪𝙡𝙖𝙩𝙞𝙤𝙣: ⚙️ Excessive bureaucracy and regulation slow innovation and increase administrative burdens. 2. 𝘾𝙤𝙨𝙩 𝙞𝙣𝙘𝙧𝙚𝙖𝙨𝙚𝙨: 💰 Rising costs for labour, logistics, raw materials and energy put pressure on companies' profit margins. 3. 𝙈𝘿𝙍 𝙞𝙢𝙥𝙡𝙚𝙢𝙚𝙣𝙩𝙖𝙩𝙞𝙤𝙣: ⏳ The high cost and effort required to comply with the EU's Medical Device Regulation (MDR) is an additional burden on the industry. For marketers, three key factors are now important: 1. 𝙄𝙣𝙘𝙧𝙚𝙖𝙨𝙚 𝙫𝙞𝙨𝙞𝙗𝙞𝙡𝙞𝙩𝙮: 👁️ Use targeted marketing to increase the visibility of your brand and products. Digital channels offer great potential for spreading your message. 2. 𝙃𝙞𝙜𝙝𝙡𝙞𝙜𝙝𝙩 𝙮𝙤𝙪𝙧 𝙞𝙣𝙣𝙤𝙫𝙖𝙩𝙞𝙤𝙣: 🗣️ The medtech industry is in desperate need of innovative solutions and your products can make a difference. 3. 𝙎𝙩𝙧𝙚𝙣𝙜𝙩𝙝𝙚𝙣 𝙘𝙤𝙡𝙡𝙖𝙗𝙤𝙧𝙖𝙩𝙞𝙤𝙣: 💪🏻 Work closely with policymakers and industry to increase the resilience of the German healthcare system. A strong community is key to success. Germany can maintain its outstanding position in medical technology, but only if we face the current challenges with courage. Together, we can protect and strengthen this location. ❗️What threats do you see for Germany as a medical technology location? Are you willing to continue investing in Germany? 🤔 #Medtech #Germany #Innovation #Marketing #Sales #MDR #Medicaltechnology #Medicaldevices #Technology Thanks to BVMed - Bundesverband Medizintechnologie https://lnkd.in/enUbPzMn

This week, the time has finally come. On thursday, we'll talk about how you can get assistive devices from application aids to mobilization aids to toileting aids into the list of assistive devices and thus into the statutory-reimbursable German medical device market. I look forward to taking you into my area of expertise and learning more about your products and strategies. #beoberlin #medicaldeviceconsultants #eumman

🚀 Key Takeaways for Success in the Highly Regulated Healthtech Market 🚀 Wellster founder Nico Hribernik and Halitus GmbH founder Dr. Sven Jungmann teamed up for a guest article in Business Insider Deutschland. Here are some of the key takeaways on how to scale in a highly regulated market… (link to article below) 🏓Prioritize Compliance: Startups in regulated markets must invest in a robust compliance infrastructure from the beginning. This builds trust with stakeholders and ensures long-term viability. 🏓Self-Regulate: Implement self-regulation measures, such as a Medical Board, to ensure adherence to safety standards and increase market acceptance. 🏓Plan for Legal Overheads: Anticipate unforeseeable legal expenses and allocate a budget for expert opinions and legal proceedings to protect your operations from potential attacks by established competitors. 🏓Invest Early in Evidence: Arm yourself with robust scientific data and publish studies in esteemed journals to defend your innovative approach against criticism and prove its value to the market. #startup #healthtech #regulation #compliance #businessstrategy #innovation #evidencebased #advisoryboard #success

[Now available, film on Israeli Medtech in comments] LSI USA 2024 had 1400 Medtech attendees! and added new angles and faces like J&J CEO Alex Gorsky and a very special session on Israel #medtech. My favorite point from each of the outstanding dialogues: - Israel Panel: Not just #StartupNation, but also #InnovationNation as reflected in the long term post-acquisition success of R&D units for Edwards Lifesciences (as Jinny L. shared 20 years in) plus Biosense Webster, Boston Scientific, Ethicon, Inc. Biosurgery, etc. With the Technion - Israel Institute of Technology and a culture fostering talent in key technical areas, the result is lower cost and higher world class talent retention than NorCal (or really anywhere). Amazing and strategic - so many US deals fail to maintain the brainpower. What will the next key technical areas in Israel be? - Alex Gorsky, Rick Anderson (launched Remicade mAB and Cypher DES, now runs a leading PE firm expert in 'Build to Buy'), and Roger Brooks panel: 'Startup CEOs are the homebuilders, Strategics are the neighborhoods.' Simple but powerful analogy. Useful for CEOs, useful for BD teams to remember. Tal Wenderow, Chris Eso, Hila Karah, Shai Policker, David Israeli, MDDavid Hochman, Joe Mullings, Iron Nation, 8400 The Health Network, Scott Pantel Revival Healthcare Capital

"Innovation Zurich is the platform that makes collaborations in the field of innovation in the Canton of Zurich visible and possible." Exciting news from the helm of Blackbeard Venture Studio! 🚀 We're now sailing with Innovation Zurich, a beacon of collaboration and innovation in the Canton of Zurich. Why This Matters: Strategic Networking: We're at the crossroads of ideas and industries, connecting with partners to spark transformative projects. Guidance Without Borders: As part of this vibrant ecosystem, we gain access to the latest in innovation, offering our clients and partners unparalleled insights. Driving Innovation: Our mission? To chart new territories in technology and industry, free from commercial constraints, fostering a future where collaboration is king. This isn't just a partnership; it's our commitment to making Zurich a lighthouse of innovation on the global map. 🌍✨ https://lnkd.in/e6RH5E9Z #bbvs #blackbeard #venture #studio #newbusiness

How do basic research findings translate into clinical applications? 👩🔬🔬💊 To develop innovative medicines and help patients, it is important to bridge the gap between basic medical research in academia and drug development in the pharmaceutical industry. An important factor is to encourage more #scientist to take a step into the #business environment. 🚀🚀 Read more about our exciting work on novel small molecule NLRP3 inflammasome activators and our ambitious plans to evolve from scientists into entrepreneurs in the latest issue of Badische Zeitung.

I always say it "too much brains in the room" prevent decision. Florian Wienbrügge learned it from you ;-) What is crucial form my PoV : the only way for a Startup to remains agile is to continuously nurture the capability for faster decision taking, appetite for risk and identify overthinking quickly. I would say that we manage this pretty well at the management level within PosterLab. How? sharpening the saw .we pay a lot of attention to listen to each other (3 managers : CTO, CEO, CPO): weekly "founders meeting" because we are highly complimentary both from a hard and soft skills perspective. .we are "self-aware" and identify better and better the given point when we start to overthink. Thank you Carsten Blau Santi Porta #startup #founders #decisiontaking Intelligent brains take longer to solve difficult problems - News - BIH at Charité (bihealth.org)